SuperworthInhibikase Therapeutics price to sales ratio IKT
Market value divided by revenue over the last twelve months, since 2022.
- Today, Oct 23, 2026
- n/m
- not a meaningful number
- Last meaningful
- 200×
- Oct 2024
- 5-year median
- 46.8×
- 5-year range
- 5.5× to 200×
- Peer median
- 2.5×
Inhibikase Therapeutics' price to sales ratio is not a meaningful number today: revenue for one or more of the four quarters through 2026-06-30 is missing, so twelve months can't be added up.
It was last meaningful in Oct 2024, at 200×.
On the days it had one over the last 5 years, its median was 46.8×, from 5.5× in May 2022 to 200× in Dec 2022.
Price to sales ratio over time
Year by year
| Year | End of year | Low | High |
|---|---|---|---|
| 2024 | 200× | 25.5× | 200× |
| 2023 | 24.2× | 16.6× | 156× |
| 2022 | 200× | 5.5× | 200× |
Against its peers
Companies in Biotechnology nearest Inhibikase Therapeutics' size, closest first, today.
| Company | Price to sales ratio |
|---|---|
| IKTInhibikase Therapeutics | n/m |
| PLXProtalix BioTherapeutics | 2.5× |
| MGTXMeiraGTx | 2.2× |
| VCELVericel | 7.1× |
| Peer median | 2.5× |
What the price to sales ratio tells you
Market value divided by revenue over the last twelve months. Useful for companies with little or no profit yet, since sales are harder to make negative than earnings.
Ignores margins entirely. A software company at 10× sales with 30% margins can be cheaper than a grocer at 1× sales with 2% margins.
More on Inhibikase Therapeutics
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.